Wada Shun-ichi, Tanaka Reiko
Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan.
Chem Biodivers. 2005 May;2(5):689-94. doi: 10.1002/cbdv.200590045.
DNA Topoisomerases (Topos) II are target enzymes for anticancer chemotherapeutic drug development. Bioassay-guided fractionation of the CHCl3 extract of the bark of Bischofia javanica led to the isolation of betulinic acid (1) and its derivatives, betulonic acid (2), 3beta-O-(Z)-coumaroylbetulinic acid (3), and 3beta-O-(E)-coumaroylbetulinic acid (4). These compounds were found to be catalytic inhibitors of Topo II activities with IC50 values ranging from 0.38 to 58 microM. The acylation of the OH group at C(3) of betulinic acid exhibited stronger Topo II inhibitory activity.
DNA拓扑异构酶II是抗癌化疗药物研发的靶标酶。对重阳木树皮的氯仿提取物进行生物测定导向的分级分离,得到了桦木酸(1)及其衍生物桦木酮酸(2)、3β - O -(Z)- 香豆酰桦木酸(3)和3β - O -(E)- 香豆酰桦木酸(4)。发现这些化合物是拓扑异构酶II活性的催化抑制剂,IC50值在0.38至58微摩尔之间。桦木酸C(3)位羟基的酰化表现出更强的拓扑异构酶II抑制活性。